Cannabis Edibles for Crohn's Disease: Relief Without Remission

Crohn's disease is the one condition on this site where a cannabis trial came close to remission, and the thing that got it there was a cigarette. In Naftali's 2013 trial at Meir Medical Center, 21 patients whose disease had beaten steroids, immunomodulators or anti-TNF drugs smoked cannabis twice a day for eight weeks, each cigarette carrying 115 mg of THC. Ten of 11 in the cannabis arm hit a clinical response against 4 of 10 on placebo, and three came off steroids. No dispensary edible resembles that, and no gastroenterologist will put it on a letterhead.

Then the trials moved to the mouth, and a pattern set in. Every time cannabinoids were measured against how a Crohn's patient feels, the number moved. Every time they were measured against what the disease is doing to the gut wall, it stayed put. An edible here is a symptom tool for pain, nausea, appetite and sleep, taken beside the biologic. It is the first gut page on the site, and it starts from the general pain evidence on our chronic pain page, because that is where cramping abdominal pain borrows its case.

What did the Crohn's cannabis trials actually test?

Three small Israeli trials, all eight weeks long. One gave smoked cannabis at 115 mg THC per cigarette, one gave 10 mg of oral CBD twice a day, and one gave an oral CBD-rich oil that also carried THC. The smoked and the THC-carrying arms moved symptom scores. CBD alone moved nothing.

The 2017 null deserves a look before a CBD gummy goes in the basket. Twenty mg of CBD a day is two Wyld Peach gummies' worth, and the authors list a small dose and missing THC among the explanations. The 2021 oil carried THC at a quarter of the CBD, so its result belongs to a combination.

Irving's 2018 pilot is ulcerative colitis, a different disease, and it gets cited for Crohn's anyway. A CBD-rich botanical extract with some THC missed its remission endpoint over ten weeks (28% against 26% on placebo), and patients took about a third fewer capsules than the placebo arm, with many adverse events put down to the THC. The Cochrane review of the Crohn's trials found three studies with 93 participants, rated the evidence very low to low certainty, and concluded the effects are uncertain, with no firm conclusions possible on efficacy or safety.

Do edibles reduce inflammation in Crohn's disease?

No human trial has shown it. In the 2021 oral trial, the cannabis arm's symptom score dropped by over a hundred points and its quality of life climbed, while the endoscopic score, CRP and calprotectin did not change. The authors concluded cannabis for Crohn's belongs inside clinical trials until more evidence arrives.

That gap between feeling and tissue is where the medical risk lives. The 2021 trial's own title draws the line, clinical response without endoscopic response, and the oral evidence has a cannabinoid shifting the first and leaving the second where it was. A drug that eases pain and improves sleep moves a symptom score whatever the bowel is doing.

Can an edible hide a Crohn's flare?

It can mute the symptoms that would otherwise signal one. In a Calgary survey of 313 IBD patients, cannabis users reported relief from abdominal pain and cramping, and Crohn's patients who had used it for more than six months had five times the odds of surgery. The study cannot say which came first.

Storr's team found 17.6% had used cannabis for IBD symptoms, almost all of it inhaled. Of those, 83.9% said it improved abdominal pain, 76.8% cramping and 28.6% diarrhoea. The surgery signal (an odds ratio of 5.03 after adjusting for tobacco, time since diagnosis and biologic use) is observational, and sicker patients plausibly reach for cannabis more often, so it proves neither direction. In a Boston survey of 292 patients, most of those using it for symptoms called it very helpful for abdominal pain, nausea and diarrhoea.

So when an edible takes the pain and the nausea down, the calprotectin test and the colonoscopy schedule stay where they were, because feeling better tells nobody whether the disease has gone quiet.

When the cannabis itself looks like a flare

Cannabinoid hyperemesis syndrome produces cyclic vomiting and abdominal pain in regular users, which a Crohn's patient and their gastroenterologist will both read as disease activity. Sorensen's 2017 systematic review of 183 sources found regular cannabis use in every case, at least weekly use in 97.4%, abdominal pain in 85.1%, and relief from hot baths in 92.3%. Stopping cannabis resolved it in 96.8%. Anyone with Crohn's who has drifted into daily, higher-dose THC and starts vomiting has a reason to mention the cannabis before the next scope gets ordered.

Does CBD cause diarrhoea?

At prescription doses, yes. In the Epidiolex trials for two childhood-onset epilepsies, diarrhoea hit 20% of patients on 20 mg per kg a day against 9% on placebo, and decreased appetite hit 22% against 5%. Those are the two problems a Crohn's patient is usually trying to fix.

The dose basis shows the gap. Twenty mg per kg is 1,400 mg a day for a 70 kg adult; at the label's lower 10 mg per kg (700 mg), diarrhoea fell to the placebo rate of 9% while decreased appetite stayed at 16%, and weight decreased sat at 3 to 5% in the table. A 10 mg CBD gummy is a seventieth of 700 mg and a 100 mg piece is a seventh, so the risk scales with whatever the label on the jar says. THC pulls the other way on appetite: dronabinol, the prescription THC capsule, is FDA-approved for anorexia with weight loss in AIDS. Whether more appetite turns into kept weight is a separate question, and our cancer cachexia page shows how it went there.

The format matters more than the ratio here. A "sugar-free" gummy sweetened with maltitol or sorbitol carries grams of sugar alcohol in every serving, which is the scale where the laxative effect shows up. For sorbitol the federal food rules spell it out: any food that reaches 50 grams of it a day in foreseeable use must carry the line "Excess consumption may have a laxative effect." Read that part of the panel before the cannabinoid ratio. Chocolates bring dairy and fat, which many Crohn's patients already avoid. And fat itself changes the dose: the Epidiolex label found a high-fat meal raised peak CBD levels fivefold. Nobody has measured how a Crohn's gut, or one shortened by resection, absorbs a swallowed cannabinoid.

Can you take edibles with infliximab or adalimumab?

No cannabinoid interaction appears on either label. The infliximab label reports no formal interaction studies, and both labels carry one cytochrome note: calming inflammation can shift levels of narrow-margin drugs such as warfarin when the biologic starts or stops. Nothing in that note involves a cannabinoid.

Ustekinumab and vedolizumab are antibodies of the same kind, proteins rather than pills. The familiar claim that CBD blocks the CYP3A4 enzyme fails on the Epidiolex label, where CBD left midazolam, a sensitive CYP3A4 test drug, unchanged. A steroid taper runs on the gastroenterologist's schedule either way.

How do people with Crohn's use edibles for symptoms?

Low and slow. Our dosing guide starts new users at 2.5 mg THC and raises it 2.5 mg at a time across separate sessions. On this page that means equal or more CBD beside the THC, evenings first because sleepiness tops Cochrane's list of side effects from the smoked trial, and several days at each step.

On flare days, drinks and mints over solids. A standard edible takes 30 minutes to 2 hours to start and runs 4 to 8 hours, per our guide to how long edibles last, while Cann lists 10 to 15 minutes for its drinks. Nausea is the other reason to sip rather than chew, and the oncology version of that problem is on our chemotherapy-induced nausea page. Four products, checked against their brand sites on October 16, 2026, with the no-chew pick first:

The Petra mint dissolves instead of being chewed, which makes it the flare-day pick, and at about $0.59 for each 2.5 mg step it is also the cheapest dose on the list. The Cann can is the pick when only a liquid will stay down, and it costs roughly seven times what a halved Wyld Peach does for the same THC. It is also the hemp-derived version Cann sells online to 39 states, and at 2 mg THC a can it sits above the 0.4 mg per-container cap that our hemp ban page dates to December 11. The Peach is the CBD-leaning maintenance piece. The Pomegranate's first step is a quarter piece, which is knife work. Wyld says dosing varies by state for both.